SCHEMBL343476

SCHEMBL343476

CC(O)c1cccc(Br)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
UGT2B7 P16662 1/20 0.47
ALDH1A1 P00352 2/20 0.45
MAPK1 P28482 1/20 0.44
HSD11B1 P28845 1/20 0.44
IDO1 P14902 1/20 0.44
TDO2 P48775 1/20 0.44
CYP3A4 P08684 3/20 0.42
CYP2D6 P10635 3/20 0.42
SLC6A2 P23975 3/20 0.42
SLC6A4 P31645 3/20 0.42
SLC6A3 Q01959 3/20 0.42
KCNH2 Q12809 1/20 0.42
MBTD1 Q05BQ5 1/20 0.41
L3MBTL3 Q96JM7 1/20 0.41
BRD4 O60885 1/20 0.41
BRD2 P25440 1/20 0.41
CREBBP Q92793 1/20 0.41
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1285074 1.00 MEN1 (0.47) MEN1KMT2AUGT2B7ALDH1A1MAPK1
SCHEMBL852720 1.00 MEN1 (0.47) MEN1KMT2AUGT2B7ALDH1A1MAPK1
SCHEMBL29626738 1.00 MEN1 (0.47) MEN1KMT2AUGT2B7ALDH1A1MAPK1
SCHEMBL1812811 0.84 SLC6A2 (0.51) ALDH1A1MAPK1IDO1TDO2CYP3A4
SCHEMBL9331663 0.83 UGT2B7 (0.56) MEN1KMT2AUGT2B7ALDH1A1CYP3A4
SCHEMBL2812852 0.83 UGT2B7 (0.56) MEN1KMT2AUGT2B7ALDH1A1CYP3A4
SCHEMBL9331659 0.83 UGT2B7 (0.56) MEN1KMT2AUGT2B7ALDH1A1CYP3A4
SCHEMBL9334664 0.83 UGT2B7 (0.56) MEN1KMT2AUGT2B7ALDH1A1CYP3A4
SCHEMBL13963168 0.83 CYP3A4 (0.47) ALDH1A1MAPK1IDO1TDO2CYP3A4
SCHEMBL11216092 0.83 ALDH1A1 (0.42) ALDH1A1MAPK1IDO1TDO2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024177860-A1 IN CHEMICO TEST FOR TOXICITY LEBRUN LABS LLC (US) 2024-08-29 WO claimed
CN-114315658-B Preparation method of sulfonate alkane ester 宁波南大光电材料有限公司 2023-06-30 CN claimed
CN-114315658-A Preparation method of sulfonate alkane ester 宁波南大光电材料有限公司 2022-04-12 CN claimed
CN-114213213-A Preparation method of fingolimod impurity 深圳市祥根生物医药有限公司 2022-03-22 CN claimed
US-4255340-A Method for preparing an alkenyl-substituted dicarboxylic acid anhydride TEXACO INC. (US) 1981-03-10 US claimed
US-12559784-B2 In chemico test for toxicity LEBRUN LABS LLC (US) 2026-02-24 US disclosed
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-01-29 US disclosed
EP-4558501-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2025-05-28 EP disclosed
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 EP disclosed
US-20250101489-A1 IN CHEMICO TEST FOR TOXICITY LEBRUN LABS LLC 2025-03-27 US disclosed
CN-116693467-B Thiazole amine MBL inhibitor and preparation method and application thereof 四川大学 2025-02-14 CN disclosed
WO-2024177860-A1 IN CHEMICO TEST FOR TOXICITY LEBRUN LABS LLC (US) 2024-08-29 WO disclosed
US-4544652-A α-Hydroxyethylphosphinates, and their use as fungicides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1985-10-01 US disclosed
US-4497960-A Chiral, optically active compounds useful as protective groups for hydroxy, thiol and amino compounds NOE CHRISTIAN (AT) 1985-02-05 US disclosed
EP-0093010-A2 Alpha-hydroxyethylphosphinates, and their production and use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1983-11-02 EP disclosed
EP-0083335-A1 Optically active chiral compounds, process for their preparation and use of these compounds in the protection of functional -OH, -SH, -NH- groups, in the separation of racemates, in the preparation of optically active imidoester hydrochlorides and of optically active esters, in the preparation of optically enriched alcohols and in the preparation of optically active compounds by asymmetric induction Noe, Christian, Dipl.-Ing. Dr. (AT) 1983-07-06 EP disclosed
US-4255340-A Method for preparing an alkenyl-substituted dicarboxylic acid anhydride TEXACO INC. (US) 1981-03-10 US disclosed
US-4064132-A ANTIINFLAMMATORY AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1977-12-20 US disclosed
US-4060528-A ANTIINFLAMMATORY JANSSEN PHARMACEUTICA N.V. (BE) 1977-11-29 US disclosed
US-4035376-A ESTERS, AMIDES, HYDROXAMIC ACIDS, ANTIINFLAMMATORY JANSSEN PHARMACEUTICA N.V. (BE) 1977-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF CBLB, CBL, CBLC MEN1 4098/4885KMT2A 1974/4885UGT2B7 843/4885
US-12559784-B2 In chemico test for toxicity ALPP, ALPI, CUTA MEN1 2759/4885KMT2A 3500/4885UGT2B7 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.